NSB 7.69% 3.6¢ neuroscientific biopharmaceuticals ltd

Ann: HREC decision to not approve Phase I Clinical Trial, page-75

ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
  1. 1,611 Posts.
    lightbulb Created with Sketch. 316
    Your comments re "increasing neuronal growth in healthy people" interested me , so I tried to do some research. I'm not a medical person but couldn't really find any down-side on any article discussing this topic, indeed, all seem to promote increasing where we can , including diet and exercise , same as building up muscle so we have peak health or a higher base line later in life from which to come down , rather than a low base line, from where we decline even further.. Considering this project started as hope for Glaucoma and has morphed into Alzheimers, Dementia and MS et al, the upside is huge and every step must be small steps, validated and proven or what just happened with SP will happen again and that will be unrecoverable for NSB.
    The CEO had to go, having presided over a continual decline of the SP since a peak 2019. The future looks good, early human trials are ongoing. GLTAH
    Last edited by Lynetteg: 10/09/22
 
watchlist Created with Sketch. Add NSB (ASX) to my watchlist
(20min delay)
Last
3.6¢
Change
-0.003(7.69%)
Mkt cap ! $5.205M
Open High Low Value Volume
3.8¢ 3.8¢ 3.6¢ $1.413K 38.14K

Buyers (Bids)

No. Vol. Price($)
1 89720 3.6¢
 

Sellers (Offers)

Price($) Vol. No.
3.9¢ 75583 1
View Market Depth
Last trade - 15.05pm 13/11/2024 (20 minute delay) ?
NSB (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.